Clinical Trial Update: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort [Phase 3]

View source ↗

Summary

Phase 3 trial update describing an all-oral, shorter, individualized regimen for rifampicin-resistant tuberculosis using contezolid, delamanid, and bedaquiline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis
• Rifampicin-resistant Tuberculosis

Drugs mentioned

• Contezolid (contezolid)
• Delamanid (Deltyba) (delamanid)
• bedaquiline (bedaquiline)

Snippet

Sponsor: Beijing Chest Hospital | Conditions: Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING